Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthRX vs Kin Meds

HealthRX
Graded #8

Higher grade

vs+13.199999999999989
Kin Meds
Graded #73

Lower grade

The verdict

HealthRX takes it — 86.1/100 to 72.9/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthRX +11
85
74
Dose & formulationKin Meds +3
90
93
Clinical oversightHealthRX +13
87
74
Labs & monitoringHealthRX +29
82
53
FulfillmentHealthRX +14
86
72
Contract termsHealthRX +30
85
55
HealthRX · left barKin Meds · right bar

The numbers

MetricHealthRXKin Meds
WeighScore86.1/10072.9/100
GradeBC
Scorecard rank#8#73
Semaglutide$189/mo$149/mo (brand Wegovy)
Tirzepatide$349/mo$149/mo (brand Zepbound)
CoverageNot publicly listedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
HealthRX

Graded #8 · B

Strengths

  • LegitScript-certified (#50087439) — a genuine, verifiable trust signal
  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard